Join us as we wrap 2021 with our annual Ophthalmology Year in Review where we will take a look back at all of the notable
deals, approvals, IPOs and M&A transactions, plus provide deeper insights and perspectives from investors, clinical thought leaders, and industry executives. Throughout the event you will be able to ask questions and make connections with other participants in real time.
PROUDLY SPONSORED BY:
Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices in Europe and Japan, and a manufacturing facility in Ireland. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU. A Phase 3 study of netarsudil ophthalmic solution is underway in Japan, in collaboration with Santen. Aerie is also pursuing additional candidates in ophthalmology, including a Phase 2b dry eye program with AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant. Aerie continues to investigate assets from its proprietary library of small-molecule multi-kinase inhibitors.
Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients.
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 2 and Phase 3 trials. For more information, please visit www.ocuphire.com.
Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical company focused on developing an innovative eye drop for the treatment of presbyopia symptoms. Promising results from a well powered Phase 2b study have paved an informed path for Orasis to advance their product candidate through successful initiation of Phase 3 studies, NEAR-1 and NEAR-2. Orasis’ differentiated formulation with an optimal balance between efficacy, safety and comfort, along with a proven commercialization strategy in place, positions the company as an emerging leader in the presbyopia space. Follow us on LinkedIn to learn more.
STAY UP TO DATE WITH OIS
STAY UP TO DATE WITH OIS
get the latest news & exclusive content!
get the latest news & exclusive content!